Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Single-arm, Target Value Clinical Trial to Evaluate the Efficacy and Safety of the Carotid Artery Stent System in the Treatment of Carotid Artery Stenosis

NCT07934563 is registered in ClinicalTrials.gov with Suzhou Zenith Vascular SciTech Limited as lead sponsor.

NCT NCT07934563 Not yet recruiting Not applicable 208 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07934563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started December 2026. Interventional study, 208 participants (estimated). Lead sponsor Suzhou Zenith Vascular SciTech Limited; China. Primary measures: Incidence of In-Stent Restenosis (ISR); Incidence of Major Adverse Events (MAE).

How it compares

119 similar trials: same condition (Carotid Stenosis) and phase

Enrollment

This trial
208
Middle half
42 to 206
Median
100
Trials with a value
119

Months from start to completion

This trial
24
Middle half
19 to 42.6
Median
29
Trials with a value
116

Sites

This trial
1
Middle half
1 to 1
Median
1
Trials with a value
103
Posted results or a linked paper 49% 58 of 119 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Single-arm, Target Value Clinical Trial to Evaluate the Efficacy and Safety of the Carotid Artery Stent System in the Treatment of Carotid Artery Stenosis
Lead sponsor
Suzhou Zenith Vascular SciTech Limited
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 1, 2028
Enrollment
208 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Atherosclerosis, Carotid Stenosis

Registry terms: carotid artery stenosis, carotid artery stenosis asymptomatic

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
China
Lead sponsor
Suzhou Zenith Vascular SciTech Limited

Arms

As registered; 1 arm.

Registered arms
Arm Type Interventions
Carotid Artery Stent System Experimental Carotid Artery Stenting

Primary endpoints

Registered primary outcome measures; 2 primary.

Registered primary endpoints
Measure Time frame
Incidence of In-Stent Restenosis (ISR) through study completion, an average of 1 year
Show registry wording

Restenosis is defined as ≥50% diameter stenosis occurring within the stent or within 5 mm of the proximal or distal stent edge of the target carotid artery, as assessed by carotid duplex ultrasound (DUS).

Incidence of Major Adverse Events (MAE) through study completion, an average of 1 year
Show registry wording

Major adverse events (MAE) are defined as the composite incidence of: (1) death, stroke (ischemic or hemorrhagic), or myocardial infarction (MI) occurring within 30 days after the procedure; and (2) death or ipsilateral ischemic stroke of the target vessel occurring from 31 to 365 days after the procedure.

Lead sponsor's other trials

Suzhou Zenith Vascular SciTech Limited, most recent start first.

Similar trials

Same condition (Carotid Stenosis) and phase, most recent start first.